SEARCH

SEARCH BY CITATION

References

  • Agadjanyan M. G. and Cribbs D. H. (2009) Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part I. CNS Neurol. Disord. Drug Targets 8, 16.
  • Alvarez V. A. and Sabatini B. L. (2007) Anatomical and physiological plasticity of dendritic spines. Annu. Rev. Neurosci. 30, 7997.
  • Bailey J. A., Maloney B., Ge Y. W. and Lahiri D. K. (2011) Functional activity of the novel Alzheimer's amyloid β-peptide interacting domain (AβID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis. Gene 488, 1322.
  • Balazs R., Vernon J. and Hardy J. (2011) Epigenetic mechanisms in Alzheimer's disease: progress but much to do. Neurobiol. Aging 32, 11811187.
  • Bauer C., Pardossi-Piquard R., Dunys J., Roy M. and Checler F. (2011) γ-Secretase-mediated regulation of neprilysin: influence of cell density and aging and modulation by imatinib. J. Alzheimers Dis. 27, 511520.
  • Beckett C., Nalivaeva N. N., Belyaev N. D. and Turner A. J. (2012) Nuclear signalling by membrane protein intracellular domains: the AICD enigma. Cell. Signal. 24, 402409.
  • Belyaev N. D., Nalivaeva N. N., Makova N. Z. and Turner A. J. (2009) Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep. 10, 94100.
  • Belyaev N. D., Kellett K. A., Beckett C., Makova N. Z., Revett T. J., Nalivaeva N. N., Hooper N. M. and Turner A. J. (2010) The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a β-secretase-dependent pathway. J. Biol. Chem. 285, 4144341454.
  • Ben Khalifa N., Tyteca D., Courtoy P. J., Renauld J. C., Constantinescu S. N., Octave J. N. and Kienlen-Campard P. (2012a) Contribution of Kunitz protease inhibitor and transmembrane domains to amyloid precursor protein homodimerization. Neurodegener. Dis. 10, 9295.
  • Ben Khalifa N., Tyteca D., Marinangeli C., Depuydt M., Collet J. F., Courtoy P. J., Renauld J. C., Constantinescu S., Octave J. N. and Kienlen-Campard P. (2012b) Structural features of the KPI domain control APP dimerization, trafficking, and processing. FASEB J. 26, 855867.
  • Berridge M. J. (1998) Neuronal calcium signaling. Neuron 21, 1326.
  • Bezprozvanny I. and Mattson M. P. (2008) Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 31, 454463.
  • Blatz A. L. and Magleby K. L. (1986) Single apamin-blocked Ca-activated K+ channels of small conductance in cultured rat skeletal muscle. Nature 323, 718720.
  • Bórquez D. A. and González-Billault C. (2012) The amyloid precursor protein intracellular domain-fe65 multiprotein complexes: a challenge to the amyloid hypothesis for Alzheimer's disease? Int. J. Alzheimers Dis. 2012, 353145.
  • Brion J. P., Couck A. M., Passareiro E. and Flament-Durand J. (1985) Neurofibrillary tangles of Alzheimer's disease: an immunohistochemical study. J. Submicrosc. Cytol. 17, 8996.
  • Buzsaki G. and Draguhn A. (2004) Neuronal oscillations in cortical networks. Science 304, 19261929.
  • Cao X. and Sudhof T. C. (2001) A transcriptively active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293, 115120.
  • Chasseigneaux S. and Allinquant B. (2012) Functions of Aβ, sAPPα and sAPPβ: similarities and differences. J. Neurochem. 120(Suppl 1), 99108.
  • De Strooper B. (2003) Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma- secretase complex. Neuron 38, 912.
  • Delrieu J., Ousset P. J., Caillaud C. and Vellas B. (2012) ‘Clinical trials in Alzheimer's disease’: immunotherapy approaches. J. Neurochem. 120(Suppl 1), 186193.
  • Di Fede G., Catania M., Morbin M. et al. (2009) A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 323, 14731477.
  • Edbauer D., Winkler E., Regula J. T., Pesold B., Steiner H. and Haass C. (2003) Reconstitution of gamma-secretase activity. Nat. Cell Biol. 5, 486488.
  • Emilsson L., Saetre P. and Jazin E. (2006) Alzheimer's disease: mRNA expression profiles of multiple patients show alterations of genes involved with calcium signaling. Neurobiol. Dis. 21, 618625.
  • Fiala J. C., Allwardt B. and Harris K. M. (2002) Dendritic spines do not split during hippocampal LTP or maturation. Nat. Neurosci. 5, 297298.
  • Fischer A., Sananbenesi F., Wang X., Dobbin M. and Tsai L. H. (2007) Recovery of learning and memory is associated with chromatin remodelling. Nature 447, 178182.
  • Flammang B., Pardossi-Piquard R., Sevalle J., Debayle D., Dabert-Gay A. S., Thévenet A., Lauritzen I. and Checler F. (2012) Evidence that the amyloid-β protein precursor intracellular domain, AICD, derives from β-secretase-generated C-terminal fragment. J. Alzheimers Dis. 30, 145153.
  • Freude K. K., Penjwini M., Davis J. L., LaFerla F. M. and Blurton-Jones M. (2011) Soluble amyloid precursor protein induces rapid neural differentiation of human embryonic stem cells. J. Biol. Chem. 286, 2426424274.
  • Glenner G. G. and Wong C. W. (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885890.
  • Goate A. and Hardy J. (2012) Twenty years of Alzheimer's disease-causing mutations. J. Neurochem. 120(Suppl 1), 38.
  • Golde T. E., Ran Y. and Felsenstein K. M. (2012) Shifting a complex debate on gamma-secretase cleavage and Alzheimer's disease. EMBO J. 31, 22372239.
  • Goodger Z. V., Rajendran L., Trutzel A., Kohli B. M., Nitsch R. M. and Konietzko U. (2009) Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway. J. Cell Sci. 122, 37033714.
  • Grundke-Iqbal I., Iqbal K., Tung Y. C., Quinlan M., Wisniewski H. M. and Binder L. I. (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83, 49134917.
  • Hama E. and Saido T. C. (2005) Etiology of sporadic Alzheimer's disease: somatostatin, neprilysin, and amyloid beta peptide. Med. Hypotheses 65, 498500.
  • Hardy J. (1997) Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20, 154159.
  • Hardy J. (2007) Does Aβ 42 have a function related to blood homeostasis? Neurochem. Res. 32, 833835.
  • Hardy J. (2009) The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J. Neurochem. 110, 11291134.
  • Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353356.
  • Heber S., Herms J., Gajic V. et al. (2000) Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J. Neurosci. 20, 79517963.
  • Hong Y., Beckett C., Belyaev N. D. and Turner A. J. (2012) The impact of amyloid precursor protein signalling and histone deacetylase inhibition on neprilysin expression in human prostate cells. Int. J. Cancer 130, 775786.
  • Huysseune S., Kienlen-Campard P., Hébert S., Tasiaux B., Leroy K., Devuyst O., Brion J. P., De Strooper B. and Octave J. N. (2009) Epigenetic control of aquaporin 1 expression by the amyloid precursor protein. FASEB J. 23, 41584167.
  • Jefferson T., Čaušević M., auf dem Keller U. et al. (2011) Metalloprotease meprin β generates nontoxic N-terminal amyloid precursor protein fragments in vivo. J. Biol. Chem. 286, 2774127750.
  • Jonsson T., Atwal J. K., Steinberg S. et al. (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 9699.
  • Jung C. K. and Herms J. (2012) Role of APP for dendritic spine formation and stability. Exp. Brain Res. 217, 463470.
  • Kametani F., Tanaka K., Ishii T., Ikeda S., Kennedy H. E. and Allsop D. (1993) Secretory form of Alzheimer amyloid precursor protein 695 in human brain lacks β/A4 amyloid immunoreactivity. Biochem. Biophys. Res. Commun. 191, 392398.
  • Kang J., Lemaire H. G., Unterbeck A., Salbaum J. M., Masters C. L., Grzeschik K. H., Multhaup G., Beyreuther K. and Muller-Hill B. (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733736.
  • Karagiannis T. C. and Ververis K. (2012) Potential of chromatin modifying compounds for the treatment of Alzheimer's disease. Pathobiol. Aging Age Relat. Dis. 2012, 2.
  • Karran E. (2012) Current status of vaccination therapies in Alzheimer's disease. J. Neurochem. 123, 647651.
  • Khachaturian Z. S. (1989) Calcium, membranes, aging, and Alzheimer's disease. Introduction and overview. Ann. N. Y. Acad. Sci. 568, 14.
  • Kienlen-Campard P., Tasiaux B. and Octave J. N. (2000) The processing and biological function of the human amyloid precursor protein (APP): lessons from different cellular models. Exp. Gerontol. 35, 843850.
  • Konietzko U., Goodger Z. V., Meyer M., Kohli B. M., Bosset J., Lahiri D. K. and Nitsch R. M. (2010) Co-localization of the amyloid precursor protein and Notch intracellular domains in nuclear transcription factories. Neurobiol. Aging 31, 5873.
  • Larson M. E. and Lesné S. E. (2012) Soluble Aβ oligomer production and toxicity. J. Neurochem. 120(Suppl 1), 125139.
  • Lauritzen I., Pardossi-Piquard R., Bauer C. et al. (2012) The β-secretase-derived C-terminal fragment of βAPP, C99, but not Aβ, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J. Neurosci. 32, 1624316255.
  • Li H., Wang B., Wang Z., Guo Q., Tabuchi K., Hammer R. E., Südhof T. C. and Zheng H. (2010) Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. Proc. Natl Acad. Sci. USA 107, 1736217367.
  • Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L. and Beyreuther K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl Acad. Sci. USA 82, 42454249.
  • Midthune B., Tyan S. H., Walsh J. J., Sarsoza F., Eggert S., Hof P. R., Dickstein D. L. and Koo E. H. (2012) Deletion of the amyloid precursor-like protein 2 (APLP2) does not affect hippocampal neuron morphology or function. Mol. Cell. Neurosci. 49, 448455.
  • Mitani Y., Yarimizu J., Saita K., Uchino H., Akashiba H., Shitaka Y., Ni K. and Matsuoka N. (2012) Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J. Neurosci. 32, 20372050.
  • Moir R. D., Lynch T., Bush A. I. et al. (1998) Relative increase in Alzheimer's disease of soluble forms of cerebral Aβ amyloid protein precursor containing the Kunitz protease inhibitory domain. J. Biol. Chem. 273, 50135019.
  • Morrissette D. A., Parachikova A., Green K. N. and LaFerla F. M. (2009) Relevance of transgenic mouse models to human Alzheimer disease. J. Biol. Chem. 284, 60336037.
  • Mucke L., Masliah E., Yu G. Q., Mallory M., Rockenstein E. M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K. and McConlogue L. (2000) High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 40504058.
  • Müller T., Concannon C. G., Ward M. W., Walsh C. M., Tirniceriu A. L., Tribl F., Kogel D., Prehn J. H. and Egensperger R. (2007) Modulation of gene expression and cytoskeletal dynamics by the amyloid precursor protein intracellular domain (AICD). Mol. Biol. Cell 18, 201210.
  • Müller T., Schrötter A., Loosse C., Pfeiffer K., Theiss C., Kauth M., Meyer H. E. and Marcus K. (2013) A ternary complex consisting of AICD, FE65, and TIP60 down-regulates Stathmin1. Biochim. Biophys. Acta 1834, 387394.
  • Nalivaeva N. N., Belyaev N. D., Zhuravin I. A. and Turner A. J. (2012a) The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it? Int. J. Alzheimers Dis. 2012, 383796.
  • Nalivaeva N. N., Beckett C., Belyaev N. D. and Turner A. J. (2012b) Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease? J. Neurochem. 120(Suppl 1), 167185.
  • Nalivaeva N. N., Belyaev N. D., Lewis D. I., Pickles A. R., Makova N. Z., Bagrova D. I., Dubrovskaya N. M., Plesneva S. A., Zhuravin I. A. and Turner A. J. (2012c) Effect of sodium valproate administration on brain neprilysin expression and memory in rats. J. Mol. Neurosci. 46, 569577.
  • Nikolaev A., McLaughlin T., O'Leary D. D. and Tessier-Lavigne M. (2009) APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457, 981989.
  • Nussbaum J. M., Schilling S., Cynis H. et al. (2012) Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β. Nature 485, 651655.
  • Ohyagi Y., Asahara H., Chui D. H. et al. (2005) Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. FASEB J. 19, 255257.
  • Palop J. J. and Mucke L. (2010) Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 13, 812818.
  • Pardossi-Piquard R. and Checler F. (2012) The physiology of the β-amyloid precursor protein intracellular domain AICD. J. Neurochem. 120(Suppl 1), 109124.
  • Pardossi-Piquard R., Petit A., Kawarai T. et al. (2005) Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of βAPP and APLP. Neuron 46, 541554.
  • Pearson H. A. and Peers C. (2006) Physiological roles for amyloid β peptides. J. Physiol. 575, 510.
  • Peleg S., Sananbenesi F., Zovoilis A. et al. (2010) Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 328, 753756.
  • Pera M., Alcolea D., Sánchez-Valle R. et al. (2013) Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathol. 125, 201213.
  • Perez-Cruz C., Nolte M. W., van Gaalen M. M., Rustay N. R., Termont A., Tanghe A., Kirchhoff F. and Ebert U. (2011) Reduced spine density in specific regions of CA1 pyramidal neurons in two transgenic mouse models of Alzheimer's disease. J. Neurosci. 31, 39263934.
  • Perreau V. M., Orchard S., Adlard P. A. et al. (2010) A domain level interaction network of amyloid precursor protein and Aβ of Alzheimer's disease. Proteomics 10, 23772395.
  • Petit A., George-Hyslop P., Fraser P. and Checler F. (2002) γ-secretase-like cleavages of Notch and βAPP are mutually exclusive in human cells. Biochem. Biophys. Res. Commun. 290, 14081410.
  • Pimplikar S. W., Nixon R. A., Robakis N. K., Shen J. and Tsai L. H. (2010) Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J. Neurosci. 30, 1494614954.
  • Priller C., Bauer T., Mitteregger G., Krebs B., Kretzschmar H. A. and Herms J. (2006) Synapse formation and function is modulated by the amyloid precursor protein. J. Neurosci. 26, 72127221.
  • von Rotz R. C., Kohli B. M., Bosset J., Meier M., Suzuki T., Nitsch R. M. and Konietzko U. (2004) The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. J. Cell Sci. 117, 44354448.
  • Santos S. F., Pierrot N., Morel N., Gailly P., Sindic C. and Octave J. N. (2009) Expression of human amyloid precursor protein in rat cortical neurons inhibits calcium oscillations. J. Neurosci. 29, 47084718.
  • Schilling S., Zeitschel U., Hoffmann T. et al. (2008) Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease-like pathology. Nat. Med. 14, 11061111.
  • Segal M. and Andersen P. (2000) Dendritic spines shaped by synaptic activity. Curr. Opin. Neurobiol. 10, 582586.
  • Stutzmann G. E. (2007) The pathogenesis of Alzheimers disease: is it a lifelong “calciumopathy”? Neuroscientist 13, 546559.
  • Tanzi R. E. and Bertram L. (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120, 545555.
  • Tanzi R. E., Kovacs D. M., Kim T. W., Moir R. D., Guenette S. Y. and Wasco W. (1996) The gene defects responsible for familial Alzheimer's disease. Neurobiol. Dis. 3, 159168.
  • Toescu E. C. and Verkhratsky A. (2003) Neuronal ageing from an intraneuronal perspective: roles of endoplasmic reticulum and mitochondria. Cell Calcium 34, 311323.
  • Turner A. J., Belyaev N. D. and Nalivaeva N. N. (2011) Mediator: the missing link in amyloid precursor protein nuclear signalling. EMBO Rep. 12, 180181.
  • Tyan S. H., Shih A. Y., Walsh J. J., Maruyama H., Sarsoza F., Ku L., Eggert S., Hof P. R., Koo E. H. and Dickstein D. L. (2012) Amyloid precursor protein (APP) regulates synaptic structure and function. Mol. Cell. Neurosci. 51, 4352.
  • Wolfe M. S. (2012) γ-Secretase as a target for Alzheimer's disease. Adv. Pharmacol. 64, 127153.
  • Xu X., Zhou H. and Boyer T. G. (2011) Mediator is a transducer of amyloid-precursor-protein-dependent nuclear signalling. EMBO Rep. 12, 216222.
  • Zhuravin I. A., Dubrovskaya N. M., Vasilev D. S., Tumanova N. L. and Nalivaeva N. N. (2011) Epigenetic and pharmacological regulation of the amyloid-degrading enzyme neprilysin results in modulation of cognitive functions in mammals. Dokl. Biol. Sci. 438, 145148.